

Name of the Issuer:		Medicamen Organics Limited	Last updated on	9th July, 2025
1	Type of Issue (IPO / FPO)		IPO	
2	Issue Size (Rs. Cr)* - Fresh Issue Size (Rs. Crores) <i>*Source: Prospectus dated June 26 ,2024 and Final Post issue report July 10, 2024</i>		10.54	
3	Grade of issue along with name of the rating agency Name Grade		Not Applicable Not Applicable	
4	Subscription Level (Number of times) <i>Source: Final Post issue report dated July 01, 2024</i> <i>*The above figure is after technical rejections</i>		685.35*	
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges			
Particulars		%		
(i) allotment in the issue ⁽¹⁾		49.86%		
(ii) at the end of 1st Quarter immediately after the listing ⁽²⁾		5.47%		
(iii) at the end of 1st FY (March 31, 2025) ⁽²⁾		3.89%		
(iv) at the end of 2nd FY (March 31, 2026)*		Not available		
(v) at the end of 3rd FY (March 31, 2027)*		Not available		
<i>*QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.</i>				
<i>(1) Source: Basis of Allotment</i>				
<i>(2) Source: Shareholding pattern as available on NSE</i>				
6	Financials of the issuer (Consolidated)			
		(In Rs. Lakhs)		
Parameters	1st FY (March 31, 2025) ⁽¹⁾	2nd FY (March 31, 2026)	3rd FY (March 31, 2027)	
Income from operations	3818.77	Not Applicable	Not Applicable	
Net Profit for the period	404.71	Not Applicable	Not Applicable	
Paid-up equity share capital	1170	Not Applicable	Not Applicable	
Reserves excluding revaluation reserves	1767.92.	Not Applicable	Not Applicable	
<i>*Financials not disclosed as reporting for the relevant fiscal year has not been completed.</i>				
<i>(1) Source: Annual Report of the Company for relevant FY.</i>				
7	Trading Status in the scrip of the issuer Company's Equity Shares are listed on NSE Limited (EMERGE Platform) The Shares have not been suspended or delisted.			
Particulars		Status		
(i) at the end of 1st FY (March 31, 2025)		Active		
(ii) at the end of 2nd FY (March 31, 2026)*		Not Applicable		
(iii) at the end of 3rd FY (March 31, 2027)*		Not Applicable		
<i>*Trading status not disclosed as the relevant fiscal year has not been completed.</i>				
8	Change in Directors of issuer from the disclosures in the offer document			
Particulars	Name of the Director	Appointed / Resigned		
(i) at the end of 1st FY (March 31, 2025)	Mr Shailesh Harimohan Gaur	Demise		
	Mr. Brijesh Kumar Chaubey	Appointment		
(ii) at the end of 2nd FY (March 31, 2026)*	Not Applicable	Not Applicable		
(iii) at the end of 3rd FY (March 31, 2027)*	Not Applicable	Not Applicable		
Source: Stock Exchange Filings				
* Changes in Directors of Issuer not updated as the relevant financial years have not been completed				

9 Status of implementation of project/ commencement of commercial production*

- (i) as disclosed in the offer document Not applicable
(ii) Actual implementation Not applicable
(iii) Reasons for delay in implementation, if any Not applicable
* The Company has not uploaded statement of deviation and utilization of funds report yet

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

(Rs. Lakhs)

Objects of the Fresh Issue	Amount
To meet Capital Expenditure requirements	400.00
Plant Updation and increase in production capacity	225.00
Funding of expenses proposed to be incurred towards Product registration in the international markets	300.00
General Corporate Purpose	39.00
Issue related expense	90.00
Total	1,054.00

Source: Prospectus dated June 26, 2024

(ii) Actual utilization

(Rs. Lakhs)

Objects of the Fresh Issue	Amount
To meet Working Capital requirements	400.00
Plant Updation and increase in production capacity	225.00
Funding of expenses proposed to be incurred towards Product registration in the international markets	41.62
General Corporate Purpose	39.00
Issue related expense	90.00
Total	795.62

Source: * The Company is yet to file statement of deviation and utilization of funds on the stock exchange

(iii) Reasons for deviation, if any

Not applicable

11 Comments of monitoring agency

(a) Comments on use of funds

(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document

Not Applicable, since Issue size is less than Rs. 100 crores

(c) Any other reservations expressed by the monitoring agency about the end use of funds

12 Pricing Data

Issue Price (Rs.):

34

Designated Stock Exchange:

NSE

Listing Date:

28-Jun-24

Price parameters	At close of listing day (June 28, 2024)	At close of 30th calendar day from listing day (July 28, 2024)	At close of 90th calendar day from listing day (September 26, 2024) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2025) ⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	144.70	83.40	65.00	21.70	159.40	19.60
NIFTY50*	24,010.60	24,836.10	26,216.05	23,585.03	25,989.42	22,140.81
NIFTY PHARMA	19,731.55	21,674.95	23,250.90	21,417.37	23,462.65	18,560.90

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2026)			As at the end of 3rd FY after the listing of the issue (March 31, 2027)		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable
NIFTY50*	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable
NIFTY PHARMA	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable

*Being index of NSE, the designated stock exchange

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.
(3) High and Low based on intra day prices
(4) In case of any reporting day falling on a holiday, previous trading day prices has been disclosed.

13 Basis for Issue Price

Accounting ratio	Name of the Company	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2025)	At the end of 2nd FY (March 31, 2026)**	At the end of 3rd FY (March 31, 2027)**
EPS	Issuer:	3.18	3.67	Not Applicable	Not Applicable
	Peer Group	Not Applicable	Not Applicable	Not Applicable	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	Not Applicable
Price to Earnings Ratio (P/E)	Issuer:	10.70	5.91	Not Applicable	Not Applicable
	Peer Group	Not Applicable	Not Applicable	Not Applicable	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	Not Applicable
RoNW(%)	Issuer:	0.16	13.78%	Not Applicable	Not Applicable
	Peer Group	Not Applicable	Not Applicable	Not Applicable	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	Not Applicable
NAV	Issuer:	17.66	25.11	Not Applicable	Not Applicable
	Peer Group	Not Applicable	Not Applicable	Not Applicable	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	Not Applicable

Notes:

(1) Sourced from Prospectus dated June 26, 2024.

* The relevant data is not available yet.

**Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

(i) Earnings per Equity Share are computed in accordance with Accounting Standard 20 "earnings per Share" notified by the Companies (Accounting Standards) Rules, 2006.

(ii) NAV per share - Net asset value per Equity Share represents net worth as at the end of the Fiscal divided by the number of Equity Shares outstanding at the end of the Fiscal

(iii) P/E - Closing Market Price as of relevant fiscal year end / Basic EPS for the Fiscal

(iv) RoNW - Return on net worth (%) is net profit attributable to equity shareholders divided by net worth for the Fiscal

(v) The company believes that there are no listed Companies in India which are focused exclusively on the segment in which they operate.

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
26-Aug-24	Considered and approved the acquisition to effectively hold 51% (on a fully diluted basis) of Depot Pharmacy Yego Ltd Rwanda for an aggregate consideration of US\$75,000
27-Sep-24	Re-appointment of M/s. N C RAJ AND ASSOCIATES, Chartered Accountants (FRN: 002249N) Delhi, as the Statutory Auditors of the Company for a period of five
08-Oct-24	Medicamen Organics Limited has acquired a 51% stake in Depot Pharmacy Yego Ltd
21-Oct-24	Company informed demise of Mr. Shailesh Harimohan Gaur (DIN: 08673822), Executive Director
28-Nov-24	Appointment of Mr. Brijesh Kumar Chaubey (DIN: 10846247), as an Additional Executive Director of the Company
30-Dec-24	Company incorporated a subsidiary company namely "Grande Etoile Pharmaceuticals Limited"
08-Jan-25	Fund raise of Rs. 3 crores by way of creating, issuing and allotting up to 4,65,910 Convertible Warrants, at a price of ₹ 64.39/- per warrant, aggregating upto ₹
13-Mar-25	Allotment of 4,65,910 fully Convertible Warrants to Mr. Bal Kishan Gupta, person belonging to "Promoter category"

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by GYR Capital Advisors Private Limited arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") and together with the BSE, the "Stock Exchanges"), as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, GYR Capital Advisors Private Limite does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither Shreni nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement.